Diabetes News and Research

Latest Diabetes News and Research

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

For the third time in four months, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a research grant aimed at helping people infected with multidrug-resistant tuberculosis. Taken together, all three NIH grants total $8.57 million.

27 Jul 2010

Insurers, young, uninsured all prepare for different changes under health reform

Insurers, the young, the uninsured and lawmakers are just a few of the groups sorting out what the implementation of health reform means for them as details emerge on changes to the system.

27 Jul 2010

Human fat tissue can be reprogrammed to yield clinically useful stem cells: Research

Australian scientists from the Monash Institute of Medical Research have "reprogrammed" adult mouse fat cells and neural cells to become stem cells that can differentiate into a variety of different cells (pluripotency). The cells, called "induced pluripotent stem cells" are nearly identical to the naturally occurring pluripotent stems cells, such as embryonic stem cells, which are highly pluripotent, in short supply and their access restricted in the U.S.

27 Jul 2010

Lack of dental insurance a problem for millions

The Philadelphia Inquirer: Lack of dental insurance is an "endemic problem" that affects millions of people, largely those without jobs, health coverage or solid incomes. "It began with a toothache. Tori Pence, 23, could feel the hole that had suddenly developed on her tooth, and she couldn't stand either hot or cold food.

27 Jul 2010

Scientists develop obesity drug without neurological side effects

The drug rimonabant was developed as a treatment for obesity and its myriad of serious health consequences. Despite having its desired effects on weight, which it decreased, and on levels of glucose and fats in the blood, rimonabant was never approved for use in the US because of serious neurological side effects including depression and anxiety. Now, a team of researchers, led by George Kunos, at the National Institutes of Health, Bethesda, and Alexandros Makriyannis, at Northeastern University, Boston, have developed a drug that has the same positive effects in mice on levels of glucose and fats in the blood as rimonabant but none of the neurological side effects.

27 Jul 2010

Roche receives FDA 510(k) clearance for CoaguChek XS Pro point-of-care anticoagulation monitor

Roche Diagnostics announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CoaguChek® XS Pro system, a new point-of-care anticoagulation monitor with a built-in bar code reader that can automatically scan and capture operator and patient identification information.

From Roche Sequencing and Life Science 27 Jul 2010

New drug for type 2 diabetes, Effect of insulin on bones

In a groundbreaking finding, a new medicine Galvus (vildagliptin) has been created for people with type 2 diabetes that would lower blood glucose levels without the side effects of other medications.

26 Jul 2010

Obesity linked to early puberty in girls

A review of more than 100 studies found overweight girls tend to reach puberty earlier than their peers do.

26 Jul 2010

Calibra Medical's Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk's Novolog

Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid acting insulin. Combining the mealtime therapy-adherence benefits of insulin pumps with the simplicity and affordability of syringes and pens, Calibra's novel bolus-only patch-pen is a small, adhesively attached, flat device that can be operated discretely through clothing to deliver mealtime, snack time, and correction bolus insulin in seconds.

26 Jul 2010

AVEO's initiation of AV-299 Phase 2 trial for lung cancer triggers $750,000 milestone payment to XOMA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc.. The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody for the treatment of non-small cell lung cancer. AV-299 is a humanized antibody to hepatocyte growth factor (HGF).

26 Jul 2010

Medtronic glucose monitoring device helps owners manage pets’ diabetes

The treatment of diabetes was revolutionized in 1922 when insulin was isolated from dogs. Since then, significant advances in human medicine have made diabetes more manageable for patients. Now, human medicine has returned the favor and used these advances to help dogs with diabetes. A University of Missouri researcher is using a continuous glucose monitoring device - commonly used in humans with diabetes - to help treat dogs and other animals. The device, which provides a detailed glucose picture of an animal over several days, will help pet owners manage their pets' diabetes.

26 Jul 2010

New guidelines for care of heart transplant recipients from ISHLT

Since the dawn of heart transplantation in the 1960s, medical care of heart transplant recipients has varied from center to center and been guided by the experience of individual clinicians. The International Society for Heart and Lung Transplantation (ISHLT) has made an unprecedented commitment by convening experts in all areas of heart transplantation to develop practice guidelines for the care of heart transplant recipients.

26 Jul 2010

Mismanagement of diabetes leads to fatal accident

One of the worst case scenarios that can happen to a diabetic is if he or she falls into a hypoglycemic coma. This is caused by a severe deficiency in glucose levels found in the blood which causes the brain to seek other energy sources at the same time shutting down other important body functions. If treatment is delayed or neglected by the diabetic person, such a coma can cause not only loss of consciousness but also irreversible brain damage and death.

26 Jul 2010

Boehringer Ingelheim announces European CHMP Positive Opinion for TWYNSTA

Boehringer Ingelheim announced today that the European Committee for Medicinal Products for Human Use (CHMP) adopted a Positive Opinion for the approval of TWYNSTA®. It will be indicated in adults whose blood pressure is not adequately controlled on amlodipine and is also indicated as replacement therapy in adult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of TWYNSTA containing the same component doses.

26 Jul 2010

HTG patients face increased risk for heart disease, stroke: Study

It can make blood look like cream of tomato soup. Patients with high levels of triglycerides in their blood, a disease called hypertriglyceridemia face an increased risk for heart disease and stroke. HTG affects one in 20 people in North America and is also associated with obesity, diabetes and pancreatitis. Most people now understand the importance of LDL, the bad cholesterol and HDL, the good cholesterol, to their overall health.

26 Jul 2010

Inhibiting fatty acid synthase can reduce atherosclerosis: Study

Scientists at Washington University School of Medicine in St. Louis have found a way to significantly reduce atherosclerosis in mice that does not involve lowering cholesterol levels or eliminating other obesity-related problems.

26 Jul 2010

Ohio sets up high risk pool; Four drug companies come under scrutiny for payments to Pittsburgh doctors, nurses

"Ohioans with pre-existing health conditions, such as cancer or diabetes, can apply for coverage under a new high-risk insurance pool beginning Aug. 1." Qualifications include evidence of a pre-existing condition, proof of Ohio residency and U.S. citizenship, state of being uninsured for six months prior to the date of applying for coverage and being "ineligible for coverage under the Medicare program, the Ohio Medical Assistance Program, the Ohio Children's Health Insurance Program, or an employer-sponsored group health plan, unless subject to a mandatory initial waiting period" (7/22).

26 Jul 2010

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard- against the human papillomavirus, which causes cervical cancer. The research will evaluate the efficacy of Carraguard- - a clear gel made from the seaweed derivative carrageenan - in preventing new HPV infections in women.

26 Jul 2010

Insurers scrambling to get expenses defined as patient care

The New York Times looks at current efforts by state insurance officials to set regulations requried under the new health overhaul about insurance company spending. "The legislative battle over the health care overhaul ended months ago, but it is hard to tell from the intense effort now under way by insurance companies to retool a critical provision.

26 Jul 2010

New data on health insurance to be included in AHRQ's 2009 State Snapshots

The Agency for Healthcare Research and Quality's annual release of state-by-state quality data has been expanded to include new data on health insurance, including data on health care quality categorized by source of payment, including private insurance, Medicare, Medicaid and those without insurance.

23 Jul 2010